Menthol; Methyl Salicylate Patent Expiration

Menthol; Methyl Salicylate was first introduced by Hisamitsu Pharmaceutical Co Inc in its drug Salonpas on Feb 20, 2008.


Menthol; Methyl Salicylate Patents

Given below is the list of patents protecting Menthol; Methyl Salicylate, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Salonpas US8809615 Adhesive preparation Jan 03, 2030 Hisamitsu Pharm Co
Salonpas US9233184 Adhesive preparation Aug 01, 2027 Hisamitsu Pharm Co


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Menthol; Methyl Salicylate's patents.

Given below is the list recent legal activities going on the following patents of Menthol; Methyl Salicylate.

Event Date Patent/Publication
Patent litigations
Payment of Maintenance Fee, 8th Year, Large Entity 02 Feb, 2022 US8809615
Payment of Maintenance Fee, 4th Year, Large Entity 08 Feb, 2018 US8809615
Email Notification 05 Oct, 2016 US8809615
Mail-Petition Decision - Denied 30 Sep, 2016 US8809615
Petition Decision - Denied 29 Sep, 2016 US8809615
Post Issue Communication - Certificate of Correction 01 Oct, 2014 US8809615
Petition Entered 04 Sep, 2014 US8809615
Recordation of Patent Grant Mailed 19 Aug, 2014 US8809615
Patent Issue Date Used in PTA Calculation 19 Aug, 2014 US8809615
Email Notification 01 Aug, 2014 US8809615



Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳